NCT07491042 Impact of SGLT2 Inhibitors on Chronic Peritoneal Dialysis Patients.
| NCT ID | NCT07491042 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Oman Ministry of Health |
| Condition | End Stage Chronic Renal Failure |
| Study Type | INTERVENTIONAL |
| Enrollment | 38 participants |
| Start Date | 2026-04-01 |
| Primary Completion | 2026-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 38 participants in total. It began in 2026-04-01 with a primary completion date of 2026-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This project aims to examine the effects of six-month treatment with selective SGLT2 inhibitor dapagliflozin in patients with end-stage kidney disease on chronic peritoneal dialysis. Methods: A prospective, open label, single-arm interventional clinical trial, will conduct at Nizwa Hospital from March 1st, 2026, to August 31th , 2026, and includes thirty (30) end-stage kidney disease diabetic and non-diabetic patients on chronic peritoneal dialysis, will receive selective SGLT2i Dapagliflozin 10 mg once daily (OD). Clinical and laboratory parameters will be assessed at baseline, then three and six months after drug initiation. The primary outcomes are:1- change in ultrafiltration volume, 2- change in Kt/V (dialysis adequacy), 3. Change in the mean 24-hour urine volume.
Eligibility Criteria
Inclusion Criteria: * o age equal to or more than13 years. * All genders. * All patients undergoing chronic Peritoneal Dialysis. * Urine output equal or more than 150 ml/24 hours. Exclusion Criteria: * o Age less than 13 years * Patients with type I diabetes mellitus. * Patients with recurrent urinary tract infection (UTI) or peripheral vascular diseases (P.V.D). * Patients with urine output less than 150 ml/24hours. * Patients with recurrent hypoglycemic episodes * Patients with acute or chronic liver disease, * Patients who refuse to participate in the study. * peritoneal Dialysis catheter (PDC) related peritonitis in last 3 months
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07491042 clinical trial?
This trial is open to participants of all sexes, aged 13 Years or older, studying End Stage Chronic Renal Failure. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07491042 currently recruiting?
Yes, NCT07491042 is actively recruiting participants. Contact the research team at sarkosyr@gmail.com for enrollment information.
Where is the NCT07491042 trial being conducted?
This trial is being conducted at Nizwa, Oman.
Who is sponsoring the NCT07491042 clinical trial?
NCT07491042 is sponsored by Oman Ministry of Health. The trial plans to enroll 38 participants.